SAR development of a series of 8-azabicyclo[3.2.1]octan-3-yloxy-benzamides as kappa opioid receptor antagonists. Part 2

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 18, 2010, Pages 5405-5410

  Brugel, Todd A ^a   Smith, Reed W ^a   Balestra, Michael ^a   Becker, Christopher ^a   Daniels, Thalia ^a   Koether, Gerard M ^a   Throner, Scott R ^a   Panko, Laura M ^a   Brown, Dean G ^a   Liu, Ruifeng ^a   Gordon, John ^a   Peters, Matthew F ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Depression; Kappa opioid antagonist

Indexed keywords

8 AZABICYCLO[3.2.1]OCTAN 3 YLOXY BENZAMIDE; KAPPA OPIATE RECEPTOR ANTAGONIST; POTASSIUM CHANNEL HERG; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CHEMICAL MODIFICATION; CONFORMATIONAL TRANSITION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; HUMAN; IC 50; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

ANIMALS; ANTIDEPRESSIVE AGENTS; BENZAMIDES; BICYCLO COMPOUNDS; BRAIN; DEPRESSIVE DISORDER, MAJOR; HUMANS; MICROSOMES, LIVER; RATS; RECEPTORS, OPIOID, KAPPA; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77956172375     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.07.112     Document Type: Article

References (19)

1. For a review see: J.V. Aldrich, and S.C. Vigil-Cruz Burger's Medicinal Chemistry and Drug Discovery 6th ed. 2003 John Wiley & Sons New York pp 329-481
2. W.A. Carlezon, C. Béguin, A.T. Knoll, and B.M. Cohen Pharm. Therap. 123 2009 334
3. P.S. Portoghese, A.W. Lipkowski, and S.E. Takemore Life Sci. 40 1987 1287
4. J.P. McLaughlin, M. Maron-Popovici, and C. Chavkin J. Neurosci. 23 2003 5674
5. Brugel, T. A.; Smith, R. W.; Balestra, M.; Becker, C.; Daniels, T.; Hoerter, T. N.; Koether, G. M.; Throner, S. R.; Panko, L. M.; Folmer, J. J.; Cacciola, J.; Hunter, A. m.; Liu, R.; Edwards, P. D.; Brown, D. G.; Gordon, J.; Ledonne, N. C.; Pietras, M.; Schroeder, P.; Sygowski, L. A.; Hirata, L. T.; Zacco, A.; Peters, M. F. Bioorg. Med. Chem. Lett. 2010. doi:10.1016/j.bmcl.2010. 07.113.
6. 50's are reported as the mean of n ≥ 2 experiments.
7. K. Schroeder, B. Neagle, D.J. Trezise, and J. Worley J. Biomol. Screening 8 2003 50
8. See Ref. 4 above for details on the preparation of 4.
9. 1H NMR and LC-MS analysis.
10. R. Schwyzer, and A. Eberle Front. Horm. Res. 4 1977 18
11. T.G. Metzger, G. Paterlini, P.S. Portoghese, and D.M. Ferguson Neurochem. Res. 21 1996 1287
12. Endo versus exo stereochemistry of the linker substitution was determined using 1D-NOESY NMR experiments.
13. T. Gaffar, and A.W. Parkins Tetrahedron Lett. 36 1995 8657
14. T. Nagase, T. Takahashi, T. Sasaki, A. Nagumo, K. Shimamura, Y. Miyamoto, H. Kitazawa, M. Kanesaka, R. Yoshimoto, K. Aragane, S. Tokita, and N. Sato J. Med. Chem. 52 2009 4111
15. D.M. Tschaen, R. Desmond, A.O. King, M.C. Fortin, B. Pipik, S. King, and T.R. Verhoeven Synth. Commun. 24 1994 887
16. Analogs from Tables 3 and 4 were synthesized according to the general procedure described in Ref. 4.
17. R.E. Dolle, M. Machaut, B. Martinez-Teipel, S. Belanger, J.A. Cassel, G.J. Stabley, T.M. Gracyzk, and R.N. De Haven Bioorg. Med. Chem. Lett. 14 2004 3545
18. M.P. Wentland, R. Lou, C. Denhardt, W. Duan, D.J. Cohen, and J.M. Bidlack Bioorg. Med. Chem. Lett. 11 2001 1717
19. M.P. Wentland, R. Lou, Y. Ye, D.J. Cohen, G.P. Richardson, and J.M. Bidlack Bioorg. Med. Chem. Lett. 11 2001 623